Azficel-T, sold under the brand name Laviv, is a cell therapy product used to treat moderate to severe nasolabial fold wrinkles, the lines running from the sides of the nose to the corners of the mouth, in adults. The treatment is autologous: fibroblasts, cells involved in skin structure and repair, are taken from a small skin sample, cultured in a laboratory to increase their number, and re-injected into the patient's own skin to improve its appearance. It was approved for medical use in the United States in June 2011.
Facts
Drug ClassPersonalized aesthetic cell therapy (autologous fibroblasts) 2 Approved UseImprovement of the appearance of moderate to severe nasolabial fold wrinkles in adults 3 First Approved / Isolated Year Classification
Approval Status Connections
Sources
1. Azficel-T (Wikipedia)
Lead sectionQuote, Lead section
Azficel-T was approved for medical use in the United States in June 2011.
2. FDA OKs autologous cell therapy (Dermatology Times)
Body, product descriptionQuote, Body, product description
personalized aesthetic cell therapy for improving the appearance of moderate-to-severe nasolabial folds in adults
3. LAVIV (azficel-T) (U.S. Food and Drug Administration)
Product page, indicationQuote, Product page, indication
Indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.
4. ChEMBL: ChEMBL molecule record for Azficel-T (CHEMBL2107865)
ChEMBLmolecule_typeQuote, molecule_type
"molecule_type": "Cell"
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.